Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2011
06/30/2011US20110159004 Methods and Compositions for Preserving the Viability of Photoreceptor Cells
06/30/2011US20110158990 5-anilinoimidazopyridines and methods of use
06/30/2011US20110158989 Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS
06/30/2011US20110158983 Compositions and methods for mucositis and oncology therapies
06/30/2011US20110158982 COMPOSITIONS AND METHODS FOR INHIBITING MAdCAM
06/30/2011US20110158980 Methods to treat and screen for agents to treat obesity
06/30/2011US20110158979 Genetic component of complications in type 2 diabetes
06/30/2011US20110158977 Immunogenic compositions for Chlamydia trachomatis
06/30/2011US20110158975 Use of runx3 and mir-532-5p as cancer markers and therapeutic targets
06/30/2011US20110158971 Compositions comprising n3 alkylated benzimidazole derivatives as mek inhibitors and methods of use thereof
06/30/2011US20110158968 Methods of making enhanced, autologous fat grafts
06/30/2011US20110158952 Compositions and methods for treating human papillomavirus-mediated disease
06/30/2011US20110158947 Sulfonylurea receptor and means for treating ischaemia
06/30/2011US20110158942 Diaryl ureas for treating virus infections
06/30/2011US20110158940 Samll molecule inhibitors for the treatment or prevention of dengue virus infection
06/30/2011US20110158935 Substituted Diketopiperazine Analogs for Use as Drug Delivery Agents
06/30/2011US20110158933 Liver function and treatment of liver disease
06/30/2011US20110158932 Methods And Compositions For The Treatment of Hyperlipidemia
06/30/2011US20110158930 Method for treatment of irritable bowel syndrome
06/30/2011US20110158921 Methods of blocking ultraviolet radiation and promoting skin growth using terpenes and terpenoids
06/30/2011US20110158920 Method of producing a composition from an oleogel and an aqueous gel and the composition
06/30/2011US20110158918 Oral cavity stimulating substance
06/30/2011US20110158917 Anti-viral tissue product with visual efficacy indicator
06/30/2011US20110158916 Anti-viral tissue product with visual indicator
06/30/2011US20110158910 Microparticles comprising polymers with thioester bonds
06/30/2011US20110158908 Cyclosporin a-binding protein
06/30/2011US20110158907 Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques
06/30/2011US20110158906 Targeted block copolymer micelles
06/30/2011US20110155130 Dronabinol Treatment for Migraines
06/30/2011DE102009060816A1 Rhodioapräparat mit Zusätzen Rhodioapräparat with additives
06/30/2011DE102009060194A1 Intermediate, useful for treating chronic hepatitis B virus infections, comprises entecavir and an auxiliary material
06/30/2011DE102009060175A1 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen Pyrrolo [2,3-d] pyrazin-7-yl-pyrimidine compounds
06/30/2011DE102009060174A1 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate Pyrrolopyridinyl-pyrimidin-2-yl-amine derivatives
06/30/2011DE102006053637B4 Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung New fluoro-substituted 1,4-benzothiepine-1,1-dioxide derivatives, pharmaceutical compositions containing them and their use
06/30/2011DE102006053635B4 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung New substituted benzyl 1,4-benzothiepine-1,1-dioxide derivatives, pharmaceutical compositions containing them and their use
06/30/2011CA2822747A1 Methods and compositions for cardiovascular diseases and conditions
06/30/2011CA2822746A1 Compositions and methods for treatment of vitiligo
06/30/2011CA2786950A1 Fused heteroaromatic pyrrolidinones as syk inhibitors
06/30/2011CA2785674A1 Novel 3-hydroxy-5-arylisothiazole derivative
06/30/2011CA2785668A1 Aminopyridine compound
06/30/2011CA2785643A1 Highly permeating terbinafine formulation for treating onychomycosis
06/30/2011CA2785553A1 Treatment of osteoporosis
06/30/2011CA2785541A1 Anticoagulant compounds and their use
06/30/2011CA2785503A1 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
06/30/2011CA2785492A1 Lipids, lipid compositions, and methods of using them
06/30/2011CA2785487A1 Solid pharmaceutical dosage form of ticagrelor
06/30/2011CA2785468A1 Sustained release delivery devices
06/30/2011CA2785451A1 Molecule for treating an inflammatory disorder
06/30/2011CA2785439A1 [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
06/30/2011CA2785434A1 Treatment for inflammatory bowel disease
06/30/2011CA2785410A1 Tyrosine bioconjugation through aqueous ene-like reactions
06/30/2011CA2785409A1 Method for predicting therapeutic effects of chemotherapy on hepatocellular carcinoma patients
06/30/2011CA2785395A1 Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer
06/30/2011CA2785389A1 Antitumor agent or postoperative adjuvant chemotherapeutic agent for hepatocellular carcinoma treatment
06/30/2011CA2785360A1 Treating critically ill patients with intravenous ibuprofen
06/30/2011CA2785353A1 Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists
06/30/2011CA2785349A1 Combination therapy for copd
06/30/2011CA2785347A1 Aerosol formulation for copd
06/30/2011CA2785340A1 Substituted isoquinolinones and quinazolinones
06/30/2011CA2785329A1 Pyrrolo[2,3-d]pyrazin-7-ylpyrimidine compounds
06/30/2011CA2785321A1 Combination therapy for copd
06/30/2011CA2785317A1 Aerosol formulation for copd
06/30/2011CA2785307A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives
06/30/2011CA2785296A1 Combination composition useful for treating cardiovascular diseases
06/30/2011CA2785284A1 Novel aryl urea derivative
06/30/2011CA2785258A1 Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
06/30/2011CA2785254A1 Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
06/30/2011CA2785253A1 Calcipotriol monohydrate nanocrystals
06/30/2011CA2785251A1 Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
06/30/2011CA2785249A1 Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture
06/30/2011CA2785191A1 Crth2 modulators
06/30/2011CA2785117A1 Transdermal therapeutic system for administering rivastigmine or derivatives thereof
06/30/2011CA2785116A1 A combination for the treatment of osteoarthritis
06/30/2011CA2785113A1 Imidazopyridine derivatives as jak inhibitors
06/30/2011CA2784996A1 Formulation comprising 1 h-quinazoline-2,4-dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof
06/30/2011CA2784894A1 Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors
06/30/2011CA2784891A1 Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
06/30/2011CA2784845A1 Use of polysaccharides for treating stress and anxiety
06/30/2011CA2784841A1 Phenol derivatives and the pharmaceutical or cosmetic use thereof
06/30/2011CA2784823A1 Phenol derivatives and pharmaceutical or cosmetic use thereof
06/30/2011CA2784822A1 Phenol derivatives and pharmaceutical or cosmetic use thereof
06/30/2011CA2784600A1 New inhibitors of cyclophilins and uses thereof
06/30/2011CA2784547A1 Influenza targets
06/30/2011CA2784393A1 Compounds and methods for kinase modulation, and indications therefor
06/30/2011CA2784242A1 New aminotetraline derivatives
06/30/2011CA2784180A1 Seven-membered ring compound and pharmaceutical use therefor
06/30/2011CA2784179A1 Emulsion composition
06/30/2011CA2784036A1 Analogues for the treatment or prevention of flavivirus infections
06/30/2011CA2783714A1 Carboxamide compounds and their use as calpain inhibitors iv
06/30/2011CA2783704A1 Carboxamide compounds and their use as calpain inhibitors
06/30/2011CA2783616A1 (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
06/30/2011CA2783575A1 Aminopyrimidine kinase inhibitors
06/30/2011CA2783543A1 Diacylglycerol acyltransferase genes and use thereof
06/30/2011CA2783475A1 Heterocyclic compounds as janus kinase inhibitors
06/30/2011CA2783340A1 Inhibitors of akt activity
06/30/2011CA2783258A1 Pteridinones as inhibitors of polo-like kinase
06/30/2011CA2783209A1 Amino-heteroaryl derivatives as hcn blockers
06/30/2011CA2782375A1 Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
06/30/2011CA2782373A1 Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
06/30/2011CA2781780A1 Novel antiviral compounds